Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2008 3
2015 1
2016 1
2017 1
2020 1
2021 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma.
Reddel HK, O'Byrne PM, FitzGerald JM, Barnes PJ, Zheng J, Ivanov S, Lamarca R, Puu M, Alagappan VKT, Bateman ED. Reddel HK, et al. Among authors: puu m. J Allergy Clin Immunol Pract. 2021 Aug;9(8):3069-3077.e6. doi: 10.1016/j.jaip.2021.04.016. Epub 2021 Apr 22. J Allergy Clin Immunol Pract. 2021. PMID: 33895362 Free article. Clinical Trial.
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, Lamarca R, Puu M, Keen C, Alagappan VKT, Reddel HK. O'Byrne PM, et al. Among authors: puu m. Lancet Respir Med. 2021 Feb;9(2):149-158. doi: 10.1016/S2213-2600(20)30416-1. Epub 2020 Oct 1. Lancet Respir Med. 2021. PMID: 33010810 Clinical Trial.
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB; CHARM Investigators. Cohen-Solal A, et al. Among authors: puu m. Eur Heart J. 2008 Dec;29(24):3022-8. doi: 10.1093/eurheartj/ehn476. Epub 2008 Nov 5. Eur Heart J. 2008. PMID: 18987098 Clinical Trial.
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA; CHARM Investigators. Weir RA, et al. Among authors: puu m. Eur J Heart Fail. 2008 Feb;10(2):157-63. doi: 10.1016/j.ejheart.2007.12.006. Epub 2008 Jan 31. Eur J Heart Fail. 2008. PMID: 18242128 Free article. Clinical Trial.
13 results